A Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 (Galcanezumab) in Japanese Patients With Episodic Migraine

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 (Galcanezumab) in Japanese Patients With Episodic Migraine

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2017

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 20 Apr 2017 Results from this trial will be presented at the American Academy of Neurology (AAN) annual meeting 2017, as reported in an Eli Lilly and Company media release.
    • 11 Nov 2016 New trial record
    • 10 Nov 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top